PATENT CLAIM ANALYSIS

Application Number: 16097322
Application Type: Utility
Filing Date: 2018-10
Publication Date: 2019-03
Patent Classification: ["540", "593000"]

Abstract:
This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.

Claim (Index 19):
The method of  claim 18 , wherein said cancer is selected from the group consisting of: brain cancer, glioblastomas, leukemias, lymphomas, Bannayan Zonana syndrome, Cowden disease, Lhermitte Duclos disease, breast cancer, inflammatory breast cancer, Wilm's tumor, Ewing's sarcoma, Rhabdomyosarcoma, ependymoma, medulloblastoma, colon cancer, gastric cancer, bladder cancer, head and neck cancer, kidney cancer, lung cancer, liver cancer, melanoma, renal cancer, ovarian cancer, pancreatic cancer, prostate cancer, sarcoma cancer, osteosarcoma cancer, giant cell tumor of bone, and thyroid cancer.

Metadata:
- Claim Count in Document: 11.0
- Percentile: 97.0
- Lexical Diversity: 1.32432
- Patent Class: 540.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15242638', '14787866', '14651711', '14794911', '13961044']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7334989575064392
- 35 USC 102 Novelty (BERT): 0.5826463377517793
- Combined Prediction Score: 0.7184136955309732
- Mean Citation Score: 374.493262
- Max Citation Score: 460.23492000000016
- Similarity Product: 433.49791148039833

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test